Abstract
You have accessJournal of UrologyBladder Cancer: Basic Research I1 Apr 2015MP36-06 P63 EXPRESSION IN BLADDER CANCER VERSUS CHRONIC BILHARZIAL BLADDER Khaled Mursi, Ayman Agag, Olfat Hammam, Essam Riad, and Mahmoud Daw Khaled MursiKhaled Mursi More articles by this author , Ayman AgagAyman Agag More articles by this author , Olfat HammamOlfat Hammam More articles by this author , Essam RiadEssam Riad More articles by this author , and Mahmoud DawMahmoud Daw More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.734AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To investigate the immunohistochemical expression of p63 in bladder cancer and the variation in this expression in relation to the histological type, grade, and stage of the tumor, and whether bilharziasis (endemic in Egypt) has an effect on its expression or not. METHODS A prospective study conducted on 70 patients divided into 3 groups, Group A: ten patients with normal healthy urothelium, Group B: 20 patients with chronic cystitis (bilharzial and non-bilharzial), and Group C: 40 patients with bladder cancer. Biopsies were taken from all patients and were examined for the expression of p63 by immunohistochemical techniques. RESULTS The mean age (±SD) for the control, cystitis, and the malignant group w as 45.2±9.5, 50.5±11.7, and 60.52±9.9 years respectively. There was a statistically significant decrease in the p63 expression and immunoreactivity in the malignancy group (p<0.05). Also, a significant decrease in the expression was found with the advancement of the tumor stage and grade (p<0.01). In Squamous cell tumors, there was a statistically significant decrease in the p63 immunoreactivity compared to transitional cell tumors (p<0.01). Regarding the impact of bilharziasis, there w as a tendency for the statistically significant decrease in the immunoreactivity in bilharzial cystitis (p<0.01), but in the malignant group, bilharziasis did not seem to affect the pattern of expression. CONCLUSIONS p63 may be a helpful biomarker and adjunct in predicting the tumor biological behavior and progression, further studies are recommended to elucidate exactly its role as a prognostic indicator and its utility as a tumor marker. Nuclear p63 immmunoreactivity Negative (0-10%), n (%) Mild (11-30%), n (%) Moderate (31-60%), n (%) Strong (61-100%), n (%) Total positive, n (%) Control, n=10 0 0 0 10 (100%) 10 (100%) Chronic cystitis, n=20 Non-bilharzial, n=10 0 0 0 10 (100%) 10 (100%) Bilharzial, n=10 0 0 3 (30%)# 7 (70%)# 10 (100%) Total, n=20 0 0 3 (15%)∗ 17 (85%)∗ 20 (100%) Malignant lesions, n=40 TCC, n=35 4 (16%) 5 (20%)ˆ 4 (16%)ˆ 12 (48%)ˆ 21 (84%) Superficial TCC, n=12 1 (8.3%) 1 (8.3%) 3 (25%) 7 (58.4%) 11 (91.7%) Invasive TCC, n=13 3 (23%)ˆ ˆ 4 (30.8%)ˆ ˆ 1 (7.7%)ˆ ˆ 5 (38.5%)ˆ ˆ 10 (76.9%)ˆ ˆ SqCC, n=15 3 (20%) 7 (46.7%) 1 (6.7%) 4 (26.6%) 12 (80%) Total, n=40 7 (17.5%)∗ 12 (30%)∗∗ 5(12.5%)∗ 16 (40%)∗∗ 33 (82.5%) Stage, n=40 Ta, n=5 0 0 1 (20%) 4 (80%) 5 (100%) T1, n=7 1 (14.3%) 1 (14.3%) 2 (28.6%) 3 (42.8%)† 6 (85.5%)† T2 - T3, n=28 6 (21.4%)‡ 11 (39.3%)‡ 2 (7.2%)†‡ 9 (32.1%)†‡ 22 (78.5%)† Grade, n=40 Grade 1, n=8 0 (0%) 1 (12.5%) 1 (12.5%) 6 (75%) 8 (100%) Grade 2, n=23 3 (13%)+ 9 (39%)+ 3 (13%) 8 (65%) 20 (87%) Grade 3, n=9 4 (44.5%)+± 2 (22.2%)+± 1 (11.1%) 2 (22.2%)+± 5 (55.5%)+± Malignant, n=40 Non-bilharzial, n=10 3 (30%) 3 (30%) 2 (20%) 2 (20%) 7 (70%) Bilharzial, n=30 4 (13.3%)& 9 (30%) 3 (10%)& 14 (46.7%)& 26 (86.6%)& # p< 0.01 compared to chronic non-bilharzial cystitis ∗ p< 0.05 compared to control cases ∗∗ p <0.01 compared to control cases ˆ p< 0.01 compared to SqCC cases ˆˆ p< 0.01 compared to superficial TCC cases † p< 0.01 compared to Ta ‡ p< 0.01 compared to T1 + p< 0.01 compared to Grade 1 ± p< 0.01 compared to Grade 2 & p< 0.01 compared to non-bilharzial malignant lesion. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e430-e431 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Khaled Mursi More articles by this author Ayman Agag More articles by this author Olfat Hammam More articles by this author Essam Riad More articles by this author Mahmoud Daw More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have